drugset / Trial / NCT04445064
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2024-06-08
- Completion
- 2025-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMSAPEPIMUT | Peptide | 100 ug | Subcutaneous |
| Subject | IO103 | Vaccine | 100 ug | Subcutaneous |